neratinib
Celcuity Studying Nerlynx Activity in HER2-Negative Breast Cancer With Hyperactive HER2 Signaling
The company will use its CELsignia test to identify metastatic breast cancer patients eligible to receive the pan-HER inhibitor with chemo within a Phase II trial.
Puma Biotechnology Provides $1.4M to NCCN-Chosen Studies of Nerlynx in Gastric Cancers
The grants will fund combination studies of neratinib in HER2-expressing gastroesophageal cancers and advanced refractory gastric cancer.
Celcuity Using CELSignia Test to Select Breast Cancer Patients for Phase II Trial of Tabrecta, Nerlynx
The company's test will identify patients who have dysregulated HER2 and c-MET signaling despite having normal HER2 expression in tumors.
JP Morgan Healthcare, Day 3 and 4: ImmunoGen, Precigen, Autolus, Exact Sciences, Jounce, and More
Drugmakers discussed advancing autologous CAR T-cell therapeutic programs, and several diagnostic firms detailed their efforts in precision oncology.